Iams Wealth Management LLC Acquires 24,964 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Iams Wealth Management acquired 24,964 Bristol Myers Squibb shares in the third quarter, valued at approximately $1.56 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb’s pipeline showed encouraging progress, with positive Phase 3 results for RYZ101 and iberdomide, while UBS said mixed admilparant results still leave the drug commercially viable.
• Analyst sentiment remains mixed but generally supportive: BMY has a consensus “Hold” rating and an average price target of $64.88, while the company offers a quarterly dividend of $0.63 per share, equivalent to a 4.2% yield.

Iams Wealth Management LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 24,964 shares of the biopharmaceutical company's stock, valued at approximately $1,558,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Guyasuta Investment Advisors Inc. lifted its position in Bristol Myers Squibb by 3.4% during the third quarter. Guyasuta Investment Advisors Inc. now owns 47,634 shares of the biopharmaceutical company's stock valued at $2,972,000 after purchasing an additional 1,563 shares during the last quarter. Walser Wealth Management Company A Ltd Liability Co grew its stake in Bristol Myers Squibb by 16.3% in the 3rd quarter. Walser Wealth Management Company A Ltd Liability Co now owns 16,731 shares of the biopharmaceutical company's stock worth $1,044,000 after buying an additional 2,350 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Bristol Myers Squibb by 2.8% in the 3rd quarter. V Square Quantitative Management LLC now owns 54,178 shares of the biopharmaceutical company's stock worth $3,381,000 after buying an additional 1,465 shares during the last quarter. First Merchants Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter worth $203,000. Finally, AdvisorNet Financial Inc increased its holdings in shares of Bristol Myers Squibb by 4.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 39,995 shares of the biopharmaceutical company's stock worth $2,371,000 after buying an additional 1,653 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress supports the investment case. Bristol Myers reported positive Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The data increase confidence that newer therapies can help offset future pressure on established products. How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb Investors
• Positive Sentiment: Admilparant remains commercially viable, according to UBS. Although the pulmonary-fibrosis drug produced mixed Phase 3 results, the lower dose met the primary endpoint, and UBS said the LPA1 antagonist still has a path forward. That assessment limits the downside from the trial news and preserves a potential new growth opportunity. Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Positive Sentiment: Some analyst support remains constructive. Truist maintained its Buy rating on BMY, helping reinforce the view that the valuation and pipeline offer upside despite ongoing execution risks. Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. HSBC reaffirmed a "hold" rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. JPMorgan Chase & Co. increased their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Daiwa Securities Group raised their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a "neutral" rating in a research report on Tuesday, August 4th. Zacks Research upgraded Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 23rd. Finally, Wells Fargo & Company dropped their price target on Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $64.88.

Bristol Myers Squibb Stock Up 2.1%

Shares of BMY opened at $60.51 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a 50 day simple moving average of $63.65 and a two-hundred day simple moving average of $60.30. The firm has a market cap of $123.60 billion, a P/E ratio of 13.33, a P/E/G ratio of 0.30 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's revenue was up 5.7% compared to the same quarter last year. During the same period last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.65 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.